Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WellsFill is a line of monophasic hyaluronic acid-based dermal fillers developed by WELLS PHARMTECH and distributed by CelestaPro. The product line includes three formulations—Fine, Deep, and Volume—designed for aesthetic soft-tissue augmentation and wrinkle correction. These fillers utilize a proprietary Complex Cross-linking Technology that combines chemical and physical cross-linking to ensure stability and longevity. Each formulation contains cross-linked hyaluronic acid (19-20 mg/mL) and lidocaine to minimize discomfort during administration. WellsFill is indicated for restoring facial volume and correcting wrinkles in areas such as the nasolabial folds, cheeks, lips, and forehead, with effects typically lasting between 8 to 12 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WellsFill.